Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Capital Expenditures (2022 - 2025)

Inhibikase Therapeutics (IKT) has disclosed Capital Expenditures for 2 consecutive years, with $13399.0 as the latest value for Q1 2025.

  • On a quarterly basis, Capital Expenditures changed N/A to $13399.0 in Q1 2025 year-over-year; TTM through Sep 2025 was $13399.0, a N/A change, with the full-year FY2023 number at $14238.0, down 94.15% from a year prior.
  • Capital Expenditures was $13399.0 for Q1 2025 at Inhibikase Therapeutics, down from $200166.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $200166.0 in Q3 2022 to a low of $13399.0 in Q1 2025.